Parabolic Drugs Ltd. IN NG, : LadcstTCHISSePLCUl? 755.

(Under Corporate Insolvency Resolution Process vide Order of Hon’ble NCLT dated 30.08.2018)

Date: 01.08.2020

National Stock Exchange of India Limited The BSE Limited , Exchange Plaza, Plot No. C-1, G Block Phiroze Jeejeebhoy Towers Dadara- Kurla Complex, Bandra (E) Dalal Street Mumbai-400051 ,; Mumbai-400001

Scrip Code-PARABDRUGS Scrip Code: 533211

Sub: Disclosure regarding of impact of CoVID-19 Pandemic on listed entities

under SEBI (Listing Obligations and Disclosure Requirements) Regulations,

2015 (“Listing Regulations”)

Ref: SEBI Circular No. SEBI/HO/ CFD/CMD1/CIR/P/2020/84 dated May 20, 2020

Dear Sirs,

Pursuant to Regulation 30 of Listing Regulations read with SEBI Circular No. SEBI/HO/

FD/CMD1/CIR/P/2020/84 dated May 20, 2020; we hereby submit the brief details

regarding the impact of COVID-19 Pandemic on the operations and performance of the

Company at consolidated level though our Company is undergoing Corporate

Insolvency Resolution Process ("CIRP") under the provisions of Insolvency and

Bankruptcy Code, 2016, in terms of order dated August 30, 2018, passed by Hon'ble

National Company Law Tribunal (NCLT), Chandigarh Bench. In terms of Section 20 of ©

Insolvency Code, the Board of the Company is suspended and the management and

operations of the Company are being managed by Resolution Professional (RP) on a

Going Concern Basis.

1. Impact of the CoVID-19 pandemic on the business:

Our Company was not in operations during the financial year 2019-20 and till date

as it is under CIRP, therefore no such impact fall upon the Company due to CoVID-

19, though our Company has Implemented “Work from Home” Policy for its

employees to ensure compliance with Government's directives and to safeguard

employee's health and safety.

2.

3.

iv.

Schedule, if any, for restarting the operations: None

Ability to maintain operations including the factories/units/office spaces

functioning and closed down:

As the Company is under CIRP, therefore no production was undertaken until the

order will be released by Hon'ble National Company Law Tribunal (NCLT),

Chandigarh Bench.

Steps taken to ensure smooth functioning of operations:

The Company has taken all preventive measures to ensure safety and well-being of

its employees and ensured all required support to its customers.

. Estimation of the future impact of COVID-19 on its operations: None

. Details of impact of CoVID-19 on Listed Entity’s:

Capital and financial resources:

As the Company was not in operation during the Financial Year 2019-20,

therefore, no impact was made on the Capital & Financial Resources of the

Company due to CoVID-19.

Profitability:

As the company was not in operation during the financial year 2019-20, therefore

no impact was made on the profitability of the Company due to CoVID-19.

Liquidity position: .

As the company was not in operation during the financial year 2019-20, therefore

no impact was made on the liquidity position of the Company due to CoVID-19.

Ability to service debt and other financing arrangements:

Company is already under CIRP hence this clause not applicable on the

Company.

Vv. Assets:

None of the Assets of the Company have been impacted or impaired by the

CoVID-19.

vi. Internal financial reporting and control:

The Company has, in all material respects, an adequate internal financial

controls system over financial reporting and are well functioning.

vii. Supply Chain: None

viii. Demand for its products/services: None

7. Existing contracts/agreements where non-fulfillment of the obligations by any

party will have significant impact on the listed entity’s business: None

8. Other relevant material updates about the listed entity’s business: None

This is for information and records.

Thanking you,

Yours Faithfully

Rashmi Gupta ““_ *«_~ (Director & Authorised Representative

On behalf of Mr. Raj Kumar Ralhan © Resolution Professional of Parabolic Drugs Limited) Regn. No. IBBI/IPA-001/IP-P00981/2017-2018/11614